<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641455</url>
  </required_header>
  <id_info>
    <org_study_id>DDC VN 10</org_study_id>
    <nct_id>NCT04641455</nct_id>
  </id_info>
  <brief_title>Use of Mucolytic Solution Before Upper Endoscopy</brief_title>
  <official_title>Use of Mucolytic Solution Before Upper Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitkovice Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitkovice Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to evaluate the effectiveness of the maximum dose of mucolytic&#xD;
      solution used before upper endoscopy on the visibility of the gastric mucosa&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Residual gastric content containing mucus, bubbles, bile and food particles may limit&#xD;
      visibility of gastric mucosa and therefore diagnostic yield of upper endoscopy, especially in&#xD;
      cases of early neoplastic lesions. Data on benefit of peroral mucolytic solution administered&#xD;
      before upper endoscopy are limited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visibility score&quot; evaluated by blinded performing endoscopist</measure>
    <time_frame>through study completion, an average of 5 months</time_frame>
    <description>Visibility score&quot; (0-25 points) counted as the sum of visibility score in the esophagus (0-5), fundus (0-5), corpus (0-5) and atrum (0-5) of the stomach and in the duodenum (0-5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visibility score&quot; evaluated by two blinded endoscopists using 10 endoscopic images captured during endoscopy</measure>
    <time_frame>through study completion, an average of 5 months</time_frame>
    <description>&quot;Visibility score&quot; (0-25 points) counted as the sum of visibility score in the esophagus (0-5), fundus (0-5), corpus (0-5) and atrum (0-5) of the stomach and in the duodenum (0-5).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Residual fluid in the stomach evaluated by blinded performing endoscopist</measure>
    <time_frame>through study completion, an average of 5 months</time_frame>
    <description>0-3 point scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of endoscopy</measure>
    <time_frame>through study completion, an average of 5 months</time_frame>
    <description>time between introduction and withdrawal of the endoscopy</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroscopy</condition>
  <arm_group>
    <arm_group_label>A mucolytic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mucolytic solution - 100 ml of water + 600 mg of N-acetylcysteine (3 tablets of 200 mg ACC long), 320 mg of simethicone (8 ml of Espumisan sir. 40 mg / ml)administered 20-30 minutes prior to upper endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B mucolytic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mucolytic solution-100 ml water + 400 mg N-acetylcysteine (2 tablets 200 mg ACC long), 20 mg simethicone (0.5 ml Espumisan sir. 40 mg / ml) administered 20-30 minutes prior to upper endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml of water 20-30 minutes prior to upper endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Espumisan, N acetylcystein</intervention_name>
    <description>Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)</description>
    <arm_group_label>A mucolytic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Espumisan, N acetylcystein</intervention_name>
    <description>Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)</description>
    <arm_group_label>B mucolytic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Administration of water before upper endoscopy</description>
    <arm_group_label>C Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18 years, signed informed consent, diagnostic gastroscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 years, interventional gastroscopy, known disease of the upper GI tract and/or&#xD;
             history of surgery of GI tract, gastroscopy indicated of bleeding, dysphagia or ileus,&#xD;
             liver cirrhosis, general anesthesia, allergy to mucolytic solution components,&#xD;
             pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Stepan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Digestive Diseases Center, Vítkovice Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michal Stepan, M.D.</last_name>
    <phone>+420595633207</phone>
    <email>stepan.michal@seznam.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Digestive Diseases Center</name>
      <address>
        <city>Ostrava</city>
        <zip>70300</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Stepan, M.D.</last_name>
      <phone>+420595633207</phone>
      <email>stepan.michal@seznam.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vitkovice Hospital</investigator_affiliation>
    <investigator_full_name>Michal Štěpán, M.D.</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

